Phase I clinical trial to investigate the maximum tolerated dose and pharmacokinetics of liposomal paclitaxel [paclitaxel] with/without capecitabine in Chinese cancer patients with advanced gastric carcinoma.

Trial Profile

Phase I clinical trial to investigate the maximum tolerated dose and pharmacokinetics of liposomal paclitaxel [paclitaxel] with/without capecitabine in Chinese cancer patients with advanced gastric carcinoma.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Capecitabine; Paclitaxel
  • Indications Gastric cancer
  • Focus Adverse reactions
  • Sponsors Nanjing Sike Pharmaceutical
  • Most Recent Events

    • 18 Apr 2009 Planned end date changed from 1 Dec 2008 to 1 Dec 2009 as reported by ClinicalTrials.gov.
    • 14 May 2008 Status changed from initiated to in progress.
    • 05 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top